News | January 25, 2026
Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Company to launch product after the expiry of semaglutide patent in India
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
India in the Changing Landscape of Life-Sciences Research & Development
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Subscribe To Our Newsletter & Stay Updated
